AbbVie (ABBV) Misses Q4 EPS by 3c, Offers FY19 Guidance
Get Alerts ABBV Hot Sheet
Join SI Premium – FREE
AbbVie (NYSE: ABBV) reported Q4 EPS of $1.90, $0.03 worse than the analyst estimate of $1.93. Revenue for the quarter came in at $8.31 billion versus the consensus estimate of $8.36 billion.
GUIDANCE:
AbbVie sees FY2019 EPS of $8.65-$8.75, versus the consensus of $8.71.
- AbbVie is issuing GAAP diluted EPS guidance for the full-year 2019 of $7.39 to $7.49. The company's 2019 GAAP guidance does not reflect non-cash charges for contingent consideration adjustments related to the expected approval of risankizumab in the first half of the year. AbbVie expects to deliver adjusted diluted EPS for the full-year 2019 of $8.65 to $8.75, representing growth of 10.0 percent at the mid-point. The company's 2019 adjusted diluted EPS guidance excludes $1.26 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments, and other specified items.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- AppFolio (APPF) Tops Q1 EPS by 17c
- PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!